Influence of uridine diphosphate-glucuronosyltransferases (1A9) polymorphisms on mycophenolic acid pharmacokinetics in patients with renal transplant

References

• Murray B, Hawes E, Lee RA, et al. Genes and beans: pharmacogenomics of renal transplant. Pharmacogenomics. 2013;14:783–798.
   PubMed Web of Science ®Google Scholar
• Sereno J, Vala H, Nunes S, et al. Cyclosporine A-induced nephrotoxicity is ameliorated by dose reduction and conversion to sirolimus in the rat. J Physiol Pharmacol. 2015;66:285–299.
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004;429:464–468.
   PubMed Web of Science ®Google Scholar
• Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13–58.
   PubMed Web of Science ®Google Scholar
• Bernard O, Tojcic J, Journault K, et al. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab Dispos. 2006;34:1539–1545.
   PubMed Web of Science ®Google Scholar
• Picard N, Ratanasavanh D, Prémaud A, et al. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005;33:139–146.
   PubMed Web of Science ®Google Scholar
• Bernard O, Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos. 2004;32:775–778.
   PubMed Web of Science ®Google Scholar
• Gong QH, Cho JW, Huang T, et al. Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics. 2001;11:357–368.
   PubMedGoogle Scholar
• Glander P, Hambach P, Braun KP, et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant. 2004;4:2045–2051.
   PubMed Web of Science ®Google Scholar
• Johnson LA, Oetting WS, Basu S, et al. Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors. Eur J Clin Pharmacol. 2008;64:1047–1056.
   PubMed Web of Science ®Google Scholar
• Girard H, Court MH, Bernard O, et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics. 2004;14:501–515.
   PubMedGoogle Scholar
• Xu L, Cai M, Shi BY, et al. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China. Transplant Proc. 2014;46:1362–1365.
   PubMedGoogle Scholar
• Le Meur Y, Büchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007;7:2496–2503.
   PubMed Web of Science ®Google Scholar
• van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008;86:1043–1105.
   PubMed Web of Science ®Google Scholar
• Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713–723.
   PubMed Web of Science ®Google Scholar
• Henderson DR, Friedman SB, Harris JD, et al. CEDIA, a new homogeneous immunoassay system. Clin Chem. 1986;32:1637–1641.
   PubMed Web of Science ®Google Scholar
• De Loor H, Naesens M, Verbeke K, et al. Stability of mycophenolic acid and glucuronide metabolites in human plasma and the impact of deproteinization methodology. Clinica Chimica Acta. 2008;389:87–92.
   PubMed Web of Science ®Google Scholar
• Guo D, Pang LF, Han YH, et al. Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers. Eur J Clin Pharmacol. 2013;69:843–849.
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Naesens M, Vermeire S, et al. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther. 2005;78:351–361.
   PubMed Web of Science ®Google Scholar
• Girard H, Villeneuve L, Court MH, et al. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab Dispos. 2006;34:1220–1228.
   PubMed Web of Science ®Google Scholar
• Baldelli S, Merlini S, Perico N, et al. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics. 2007;8:1127–1141.
   PubMed Web of Science ®Google Scholar
• Xie XC, Li J, Wang HY, et al. Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients. Acta Pharmacol Sin. 2015;36:644–650.
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant. 2006;6:1111–1131.
   PubMed Web of Science ®Google Scholar
• Kaplan B. Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome. Curr Med Res Opin. 2006;22:2355–2364.
   PubMed Web of Science ®Google Scholar
• Inoue K, Miura M, Satoh S, et al. Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Ther Drug Monit. 2007;29:299–304.
   PubMed Web of Science ®Google Scholar
• Rovin BH, McKinley AM, Birmingham DJ. Can we personalize treatment for kidney diseases? Clin J Am Soc Nephrol. 2009;4:1670–1676.
   PubMed Web of Science ®Google Scholar
• Korprasertthaworn P, Rowland A, Lewis BC, et al. Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity. Biochem Pharmacol. 2012;84:1511–1521.
   PubMed Web of Science ®Google Scholar
• Pazik J, Ołdak M, Lewandowski Z, et al. Recipient uridine 5′-diphospho-glucuronosyltransferase UGT1A9 c.98T > C variant determines transplanted kidney filtration rate. Transplant Proc. 2014;46:2678–2682.
   PubMed Web of Science ®Google Scholar
• Hesselink DA, van Hest RM, Mathot RAA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5:987–994.
   PubMed Web of Science ®Google Scholar
• Mazidi T, Rouini MR, Ghahremani MH, et al. Impact of UGT1A9 polymorphism on mycophenolic acid pharmacokinetic parameters in stable renal transplant patients. Iran J Pharm Res. 2013;12:547–556.
   PubMed Web of Science ®Google Scholar
• van Schaik RH, van Agteren M, De Fijter JW, et al. UGT1A9-275T > A/-2152C > T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther. 2009;86:319–327.
   PubMed Web of Science ®Google Scholar
• Michelon H, Konig J, Durrbach A, et al. SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics. 2010;11:1703–1713.
   PubMed Web of Science ®Google Scholar
• Ting LSL, Benoit-Biancamano M-O, Bernard O, et al. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study. Pharmacotherapy. 2010;30:1097–1108.
   PubMed Web of Science ®Google Scholar
• van Agteren M, Armstrong VW, van Schaik RH, et al. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G > A gene polymorphism. Ther Drug Monit. 2008;30:439–444.
   PubMed Web of Science ®Google Scholar